moneyheap
NVST · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Envista Holdings Corporation Common stock (NVST) stock moving?
Envista reported Q3 2026 results on Nov 4: sales of $691M (core sales growth 2.7%), adjusted EPS of $0.40 (+25% year over year) against a $0.36 estimate, and adjusted EBITDA up 9% to $106M with margin up 80 bps to 15.3%. Management raised FY2026 adjusted EPS guidance to $1.54-$1.58 from $1.50-$1.55, above the $1.53 consensus. GAAP net income of $508M and GAAP EPS of $3.11 were inflated by a non-cash $428M foreign currency translation gain, so GAAP figures do not reflect operating strength. Free cash flow was $63M versus $68M a year earlier. The stock jumped to a $27.37 intraday high and closed at $27.19 on Nov 4 on 6.1M shares, roughly double the late-October average. It then fell to $24.96 on Nov 5 as BofA cut its target to $30 from $34, and recovered to $25.84 on Nov 10 on falling volume. Analyst views remain constructive: Evercore ISI keeps Outperform with a $30 target and UBS keeps Neutral with a $29 target, implying about 12-16% upside from the current price. The Nov 9 mixed shelf prospectus signals possible future share issuance, though terms are undisclosed. The stock is about 5-6% below its Nov 4 peak, and the $24.1-$24.6 zone held during the pullback.
News behind the analysis
- Envista Holdings Q3 Adj. EPS $0.40 Beats $0.36 Estimate, Sales $691.500M Beat $688.733M EstimateQ3 adjusted EPS of $0.40 and sales of $691.5M both beat consensus estimates.
- Envista Holdings Raises FY2026 Adj EPS Guidance from $1.50-$1.55 to $1.54-$1.58 vs $1.53 EstFull-year 2026 adjusted EPS guidance was raised to $1.54-$1.58, above the $1.53 consensus.
- Envista Holdings Corporation Reports Third Quarter 2026 Financial ResultsCompany reported profitable growth in Q3 and raised full-year earnings guidance; GAAP results include a $428M non-cash currency translation gain.
- Evercore ISI Group Maintains Outperform on Envista Holdings, Raises Price Target to $30Evercore ISI kept its Outperform rating and lifted its price target to $30.
- BofA Securities Adjusts Envista Price Target to $30 From $34BofA Securities lowered its price target on Envista from $34 to $30.
- UBS Maintains Neutral on Envista Holdings, Raises Price Target to $29UBS kept a Neutral rating and raised its price target to $29.
- Envista Holdings Files Prospectus For Offering Mixed Shelf; Terms UndisclosedEnvista filed a prospectus for a mixed shelf offering; offering terms were not disclosed.
About Envista Holdings Corporation Common stock, $0.01 par value per share
Envista Holdings is a dental products company based in Brea, California, that was spun off from Danaher in 2019. It owns brands such as Nobel Biocare (implants), Spark and Invisalign rival aligners, Ormco (orthodontics), Kerr (consumables) and DEXIS (imaging), and it sells to dentists and dental labs around the world.
How it makes money
It sells dental products through two segments. Specialty Products & Technologies covers implants, orthodontics and clear aligners, and brings in a little more than half of sales. Equipment & Consumables covers imaging systems and everyday supplies like restorative materials. Annual revenue is roughly $2.8 billion, for example about $691 million in Q3 2026. A large share of sales comes from repeat purchases of consumables and implants.
What usually moves NVST
- Patient visits and spending on elective dental procedures
- China volume-based procurement (VBP) pricing for implants
- Clear aligner and implant competition and market share
- Margin gains from cost cutting and pricing
- Dentist spending on new equipment and imaging